Protecting Cardiorenal Function In Diabetic Kidney Disease
Dhiren Patel, PharmD, and Bob Busch, MD, interview Fatima Cody Stanford, MD, MPH, MPA, an obesity medicine specialist, to examine the cardiovascular (CV) impact of obesity and delve into the potential benefits of newer weight loss medications in mitigating CV risk and heart failure.
1:27 Diabetes, kidney disease, and CV risk interrelationship
3:54 Expanding indications for SGLT2 inhibitors for CV risk reduction
5:40 CV benefits of SGLT2 inhibitors in clinical trials
7:20 Use of finerenone for CKD
9:20 Using stage and severity of CKD to guide treatment choice
14:00 Benefits of combining finerenone with SGLT2 inhibitors
16:30 Potential use of GLP 1 agonists for CKD
19:20 Considerations for incorporating therapies for CKD
23:00 Key takeaways on using new treatments for CKD
